orforglipron calcium · Eli Lilly And Co · NDA 220934
Foundayo
Earliest generic entry, as listed · earliest of 6 marketed strengths
26 Sep 2037
Blocked by patent: US RE50455.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US RE50455 | drug substance, drug product, use U-4474 · sets the listed date | 26 Sep 2037 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 1 Apr 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220934 · 001 · RLD | tablet, oral | EQ 0.8MG BASE | 26 Sep 2037 |
| 220934 · 002 · RLD | tablet, oral | EQ 2.5MG BASE | 26 Sep 2037 |
| 220934 · 003 · RLD | tablet, oral | EQ 5.5MG BASE | 26 Sep 2037 |
| 220934 · 004 · RLD | tablet, oral | EQ 9MG BASE | 26 Sep 2037 |
| 220934 · 005 · RLD | tablet, oral | EQ 14.5MG BASE | 26 Sep 2037 |
| 220934 · 006 · RLD | tablet, oral | EQ 17.2MG BASE | 26 Sep 2037 |